 |
|
|
| |
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: The EXPEDITION-2 Study
|
| |
| |
Reported by Jules Levin
EASL 2017 Amsterdam, Netherlands April 19-21
Juergen Rockstroh1, Karine Lacombe2, Rolando M Viani3, Chloe Orkin4, David Wyles5, Annie Luetkemeyer6, Ruth Soto-Malave7, Robert Flisiak8, Sanjay Bhagani9, Kenneth E Sherman10, Tatina Shimonova11, Peter Ruane12, Joseph Sasadeusz13, Jihad Slim14, Zhenzhen Zhang3, Teresa I Ng3, Abhishek Gulati 3, Nancy S Shulman3, Roger Trinh3, Mark Sulkowski15
1Universitätsklinikum Bonn, Bonn, Germany; 2Inserm UMR-S1136, Université Pierre et Marie Curie, Hôpital Saint-Antoine, APHP, Paris; 3AbbVie Inc., North Chicago, Illinois, United States; 4The Royal London Hospital, London, United Kingdom; 5Denver Health Medical Center, Denver, Colorado, United States; 6Zuckerberg San Francisco General, San Francisco, California, United States; 7Innovati ve Care P.S.C., Bayamon, Puerto Rico; 8Klinika Chorób Zakaznych i Hepatologii UM w Biaymstoku, Biaystok, Poland; 9Royal Free London Foundati on Trust, London, United Kingdom; 10University of Cincinnati , Cincinnati , Ohio, United States; 11State Budgetary Healthcare Insti tuti on Infecti ous Clinical Hospital #2 of Moscow City Healthcare Department, Moscow, Russia; 12Ruane Medical & Liver Health Insti tute, Los Angeles, California, United States; 13Royal Melbourne Hospital, Parkville, Victoria, Australia; 14St. Michael's Medical Center, Newark, New Jersey, United States; 15Johns Hopkins University School of Medicine, Balti more, Maryland, United States
|
| |
|
|
|
|
|
